[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ischemia-myocardial\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ischemia-myocardial":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,80],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100588182","imaging-and-treatment-planning-for-cardiac-radioablation-100588182",false,"NCT06938074","Imaging and Treatment Planning for Cardiac Radioablation","ITPCR","Inclusion Criteria\n\n* Ischemic cardiomyopathy with monomorphic VT\n* Referred by cardiologists\n* 18 years of age or older Exclusion Criteria\n* • Polymorphic ventricular tachycardia\n* Ventricular fibrillation\n* Pregnant or breastfeeding or planning to become pregnant or breastfeed during the study\n* Estimated glomerular filtration rate ≤ 30 mL\u002Fmin\u002F1.73m2\n* Previous allergic reaction to CT contrast agent Note that participants with contraindications for MRI can still be enrolled in this study but will not undergo MRI parts of this protocol.","ALL","18 Years",{"count":19,"type":20},15,"ESTIMATED","INTERVENTIONAL",[23],"NA","Cardiac radioablation is a new treatment for ventricular tachycardia (VT), which uses beams of radiation to treat heart scar that causes VT. To identify the scar areas, magnetic resonance imaging (MRI) and computed tomography (CT) imaging are often used. These are both types of medical imaging that allow clinicians to examine scar area without having to do invasive surgery.\n\nResearchers have developed new heart imaging protocols using both MRI and CT. Their MRI protocol method can now spot both dense and scattered scar tissue. The CT protocol combines multiple different types of scans into a single appointment and uses a special scanner that captures the motion of the heart. For this study, patients will undergo CT and MRI imaging according to these new imaging protocols.\n\nWith this study, researchers aim to show that these new imaging protocols can be undergone by patients with ventricular tachycardia and can be used to identify scar. Researchers will also use these scans to make radiation treatment plans to identify which types of treatment can be delivered safely to patients.",[26,27,28],"Ventricular Tachycardia, Monomorphic","Ventricular Tachycardia (V-Tach)","Ischemia, Myocardial",[30,31,32,33,34,35],"Cardiac radioablation","Stereotactic arrhythmia radioablation","Ischemic fibrosis","Late iodine enhancement CT","CT perfusion","Late gadolinium enhanced MRI","NOT_YET_RECRUITING","2025-09-22",{"date":39,"type":40},"2025-09-26","ACTUAL",{"date":42,"type":20},"2025-11-01",{"date":44,"type":20},"2026-09-01",{"name":46,"class":47},"Stewart Gaede","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":57,"targetDuration":59,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":48},"100561290","inoca-na-a-local-prospective-registry-100561290","NCT06588244","INOCA-NA a Local Prospective Registry","Ischemia in Patients with Non- Obstructive Disease (INOCA) - a Local Prospective Registry (INOCA-Naples)","INOCA-NA","Inclusion Criteria:\n\n* Clinical presentation of chronic ischemic heart dis- ease (IHD), requiring coronary angiography for the diagnosis;\n* Absence of obstructive coronary artery disease (CAD) at coronary angiography;\n* Age \\> 18 years.\n* Ability to provide a valid informed consent to the study procedure at the time of baseline evaluation;\n\nExclusion Criteria:\n\nClinical presentation of acute coronary syndrome (ACS) or cardiogenic shock;\n\n* Presence of obstructive CAD with at least 1 significant coronary artery stenosis, defined as diameterstenosis \\>50% and FFR ≤0.80 (or iFR\u002FRFR ≤0.89);\n* Previous coronary artery bypass grafting (CABG);\n* Left ventricular systolic dysfunction, defined as ejection fraction (EF) \\<40%;\n* Severe valvular heart disease;\n* Pregnant or breastfeeding women\n* Known hypersensitivity or contraindication to any of the drugs used for coronary physiology testing (adenosine, nitrates, acetylcholine)\n* Inability or unwillingness to provide a valid in- formed consent to the study procedure at the time of baseline evaluation.",{"count":58,"type":20},250,"1 Year","OBSERVATIONAL","The present study has the following objectives:\n\n1. To investigate the prevalence of INOCA in patients referring for a clinically indicated coronary angiography (CA) c\u002Fo Division of Cardiology - Federico II University Hospital;\n2. To stratify in INOCA endotypes patients according to the presence or absence of alternative (i.e. non obstructive CAD) causes of myocardial ischemia detected during CA clinically indicated through physiology tests;\n3. to implement a stratified therapy in these patients considering the different INOCA endotypes and evaluate the impact on angina class and quality of life as well as cardiac hospitalization and coronary revascularization during 5 year follow up",[28,63,64,65],"Non-Obstructive Coronary Atherosclerosis","Microcirculatory Status","Coronary Microvascular Dysfunction (CMD)",[67,68,69],"INOCA","CMD","VSA","RECRUITING","2025-03-12",{"date":73,"type":40},"2025-03-17",{"date":75,"type":40},"2024-09-19",{"date":77,"type":20},"2027-09-01",{"name":79,"class":47},"Federico II University",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":21,"phases":90,"briefSummary":91,"conditions":92,"keywords":95,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":5},"100569276","comparison-of-an-ultra-low-strut-thickness-everolimus-eluting-biodegradable-polymer-stent-versus-durable-polymer-everolimus-eluting-stents-in-patients-treated-with-percutaneous-coronary-intervention-100569276","NCT06692140","Comparison of an Ultra-low Strut Thickness Everolimus-eluting Biodegradable Polymer Stent Versus Durable Polymer Everolimus-eluting Stents in Patients Treated with Percutaneous Coronary Intervention","Randomized Comparison of an Ultra-low Strut Thickness Everolimus-eluting Biodegradable Polymer Stent Versus Durable Polymer Everolimus-eluting Stents in Patients Treated with Percutaneous Coronary Intervention in an All Comer Population (The SORT OUT XII Trial)","SORT OUT XII","Inclusion Criteria:\n\n* All patients aged ≥18 years who are eligible for treatment with one or several drug-eluting coronary stents\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Not able to consent to study participating (eg. intubated patients)\n* Unstable circuit or in cardiogenic shock and therefore not able to understand the information and purpose of the study\n* Do not speak Danish\n* Already included in the SORT OUT XII study\n* Life expectancy \\\u003C1 year\n* Allergic to study related treatment",{"count":89,"type":20},3150,[23],"The objective of this randomized study is to compare the safety and efficacy of the ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent to the everolimus-eluting family stents (durable polymer everolimus-eluting Xience or Promus stents) in a population-based setting with coronary artery stenosis treated with percutaneous coronary intervention",[28,93,94],"Coronary Artery Disease","Percutaneous Coronary Intervention (PCI)",[96,97],"Drug-eluting stent","outcome","2024-12-04",{"date":100,"type":40},"2024-12-09",{"date":102,"type":40},"2024-11-16",{"date":104,"type":20},"2032-07-01",{"name":106,"class":47},"Odense University Hospital"]